A carregar...

Pathogen Acquisition in Patients with Cystic Fibrosis Receiving Ivacaftor or Lumacaftor/Ivacaftor

BACKGROUND: The CFTR modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infect...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Pulmonol
Main Authors: Singh, Sachinkumar B., McLearn-Montz, Amanda J., Milavetz, Francesca, Gates, Levi K., Fox, Christopher, Murry, Logan T., Sabus, Ashley, Porterfield, Harry S., Fischer, Anthony J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6641998/
https://ncbi.nlm.nih.gov/pubmed/31012285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!